Article Information
History
- June 30, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Liis Leitsalu*,1,
- Marili Palover*,1,2,
- Timo Tõnis Sikka1,2,
- Anu Reigo1,
- Mart Kals1,3,
- Kalle Pärn1,3,
- Tiit Nikopensius1,
- Tõnu Esko1,
- Andres Metspalu1,2,
- Peeter Padrik5,6 and
- Neeme Tõnisson**,1,4
- 1Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia
- 2Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
- 3Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
- 4Dept. of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia
- 5Hematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia
- 6Institute of Clinical Medicine, University of Tartu, Tartu, Estonia
- ↵**corresponding author email address: neeme.tonisson{at}ut.ee
↵* These authors contributed equally to this work
Posted June 30, 2020.
Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants
